InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7
To access the live teleconference, dial 888-799-0528 (U.S.) or706-634-0154 (international), conference ID#32601453. To access the webcast,please log on to the company's website at http://www.intermune.com at least 15minutes prior to the start of the call to ensure adequate time for anysoftware downloads that may be required.
A replay of the webcast and teleconference will be available approximatelythree hours after the call. The teleconference replay will be available for10 business days following the call and can be accessed by dialing800-642-1687 (U.S.) or 706-645-9291 (international), and entering theconference ID#32601453.
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolioincludes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as apossible therapeutic candidate for the treatment of patients with IPF and aresearch program focused on small molecules for pulmonary disease. Thehepatology portfolio includes the HCV protease inhibitor compound ITMN-191(R7227) in Phase 1b, a second-generation HCV protease inhibitor researchprogram, and a research program evaluating a new target in hepatology. Foradditional information about InterMune and its R&D pipeline, please visithttp://www.intermune.com.
SOURCE InterMune, Inc.
You May Also Like